资讯

行业新闻

与原料药、中间体及成品制剂伙伴相关的授权交易、监管决策与市场动态。

2026.07.17industry

Eli Lilly Acquires AtaiBeckley for $2.8B, Signaling Big Pharma's Psychedelics Push and New Controlled Substance API Demand

Eli Lilly acquires psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, marking the strongest signal yet that large pharmaceutical companies are embracing psychedelic-assisted therapies for treatment-resistant depression and creating new demand for controlled substance API manufacturing.

2026.07.17industry

FDA Approves Merck's Lipfrendra, the First Oral PCSK9 Cholesterol Pill, Ushering in New Era for Small-Molecule Cardiovascular APIs

Merck secures FDA approval for Lipfrendra (enlicitide), the first oral PCSK9 inhibitor, replacing injectable biologics with a daily pill and creating massive demand for complex small-molecule API manufacturing in the cardiovascular space.

2026.07.16industry

Merck's ADC sac-TMT Shows Potential to Replace Chemotherapy in Front-Line Lung Cancer, Signaling ADC Manufacturing Demand

Merck's Phase 3 OPTiTROP-Lung06 trial demonstrates that sac-TMT, a novel antibody-drug conjugate, could replace traditional chemotherapy in first-line non-small cell lung cancer, with Wall Street analysts calling it 'direct proof-of-concept' for ADC-based treatment standards and creating massive demand for ADC manufacturing infrastructure.

2026.07.16industry

FDA Approves Celcuity's Revtorpyk for Breast Cancer Despite Launch Delay Concerns, Signaling New API Demand

FDA approves Celcuity's novel breast cancer drug Revtorpyk, though shares fell 20% after the company revealed launch delays and prescribing information details that surprised analysts, creating both opportunities and uncertainties for API suppliers in the oncology market.

2026.07.15industry

Biogen's Tau-Targeting ASO BIIB080 Shows 26% Cognitive Decline Slowing in Alzheimer's Phase 2 Trial, Signaling ASO Manufacturing Demand

Biogen's Phase 2 Celia trial of BIIB080, a tau-targeting antisense oligonucleotide developed with Ionis, demonstrates 26% slowing of cognitive decline comparable to Leqembi, validating tau reduction as a viable Alzheimer's strategy and creating massive potential demand for ASO manufacturing capacity.

2026.07.15industry

Avere Therapeutics Licenses Hansoh's Oral IL-23 Inhibitor for Psoriasis in 20M Reverse Merger Deal

Avere Therapeutics, led by ex-Akero executives, reverse merges with NextCure and secures 20M to advance Hansoh Pharmaceutical's long-acting oral IL-23 inhibitor AVR-001, positioning it as a potential challenger to AbbVie's Skyrizi and J&J's Icotyde in the 0B+ psoriasis market.

2026.07.14industry

Revolution Medicines' Daraxonrasib Delivers Landmark Pancreatic Cancer Results, Signaling Massive RAS Inhibitor API Demand

Revolution Medicines' novel RAS(ON) inhibitor daraxonrasib achieves breakthrough clinical results in pancreatic cancer that oncologists compare to the arrival of checkpoint inhibitors, with peak sales estimates of $5-8B driving urgent demand for complex small-molecule API manufacturing and specialized intermediates.

2026.07.14industry

GSK Terminates $2.2B Alector Neuroscience Deal After Dual Clinical Failures

GSK officially ends its neuroscience collaboration with Alector following clinical failures for both latozinemab and a second antibody program, highlighting persistent challenges in CNS drug development and creating supply chain uncertainty for neuroscience biologics manufacturers.

2026.07.13industry

GSK and Hansoh's B7-H3 ADC Extends Survival in Phase 3 Lung Cancer Trial, Signaling ADC Manufacturing Demand

GSK and Hansoh Pharmaceutical report positive Phase 3 results for HS-20093, a B7-H3-targeting ADC that improves overall survival in second-line NSCLC, validating a novel target class and expanding demand for ADC manufacturing infrastructure and specialized linker-payload intermediates.

2026.07.13industry

ARPA-H Launches $160M Initiative to Scale Custom CRISPR Gene Editing for Rare Diseases

ARPA-H invests $160M in seven research teams to build scalable manufacturing for personalized CRISPR therapies, inspired by Baby KJ's success — creating new supply chain opportunities in guide RNA synthesis, lipid nanoparticles, and GMP-grade gene editing reagents.

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →